COMP vs FSV

Compass, Inc. exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it in the 'Weak' health category. While the company maintains strong top-line revenue growth of 23.10% and a low Price/Sales ratio of 0.84, these are offset by negative profit margins, a negative ROE of -9.79%, and a concerning liquidity position with a current ratio of 0.86. There is a stark disconnect between the bullish analyst target price of $13.25 and the internal reality of consistent earnings misses (0/4 beats in the last year) and aggressive insider selling by the CFO and General Counsel.

FSV demonstrates exceptional fundamental health with a Piotroski F-Score of 8/9, signaling strong operational efficiency and financial stability. However, the stock is trading at a significant premium, with a current price of $145.74 far exceeding both its Graham Number ($46.33) and Intrinsic Value ($93.52). While earnings growth is robust at 19.5% and analysts maintain a bullish target of $207, the technical trend is severely bearish (0/100) with a 20.5% decline over the last six months. The investment case currently rests on a conflict between high-quality internal health and an overextended valuation in a downward price trend.